- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Louis Tharp: Drivers of High Drug Costs
Louis Tharp, cofounder and executive director of the Global Healthy Living Foundation, discusses what drives high drug costs in the United States.
Transcript:
What are some factors that are driving high costs of prescription drugs? Are pharmacy benefit managers playing a role here?
It’s really a diminishing returns issue here. When [pharmacy benefit managers, PBMs] first started, they were the administrative arm. They were the folks who tracked the distribution of drugs to patients, and they typically charged 10%.
Today, and today is kind of a metaphor here, they then found out that they could make a lot more money if they became more active. They were spun off as independent companies, they were free to do that, and while no one was watching, they took over the healthcare system in the [United States]. It’s not for the good of patients. Now, it’s a multi-billion-dollar monster that needs to be fed. I think Express Scipts' profits for 2017 were over $4 billion.
That’s money that doesn’t go to patients. At [Global Healthy Living Foundation, GHLF], we wonder whether that’s money that even needs to be in circulation. If you look at Medicare, it allocates 98 cents of every dollar to patient care. It’s the most efficient healthcare program in the United States, probably in the top 10 in the world. So, we know how to do this.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
